INTRODUCTION
Malaria, the world's most deadly parasitic disease, is caused by Plasmodium species which are transmitted by female Anopheles mosquitoes. In 2015, 210 million cases of malaria and almost 430000 deaths due to the parasite a , in particular by P. falciparum, were listed. In drug resistance areas, recommended by WHO since 2001, several antimalarial drugs, such as mefloquine (MQ) or lumefantrine (LM), are currently used in combination with artemisinin derivatives (ACTs). a,b However, the emergence of multidrug-resistant parasites, including artemisinin, is a real problem of public health. We have previously developed an asymmetric synthesis to prepare enantiopure 4-aminoquinoline-methanols (AQMs) as MQ analogs. They were active in the nanomolar range against 3D7 (chloroquine-sensitive) and W2 (chloroquine-resistant) P. falciparum strains (Table 1) . c Interestingly, (S)-enantiomers displayed an activity increased by 2 to 15-fold as compared to their (R)-counterparts. c,d In order to obtain new antimalarial agents and evaluate the heterocyclic modification (fluorene vs quinoline) on the antimalarial activity, we describe here, the syntheses of enantiopurs 4-aminofluorenemethanols (AFMs) as LM analogs. We will establish novel structure-activity relationships (SAR), with several structural modifications, and we will compare the AFMs antimalarial activities with the AQMs previously obtained.
74.7 ± 4.7 38,2 ± 3.6 (S)-1b (n=4) 205 ± 16.2 142 ± 13.8 (R)-1b (n=4) 14.5 ± 1.2 9.4 ± 0.9 (S)-1c (n=5) 33.0 ± 1.6 ND 1 (R)-1c (n=5) 254 ± 27 ND 1 The in vitro antimalarial activities of AFMs 2 were evaluated against 3D7 and W2 P. falciparum strains with ELISA HRP2 method. The hypoxanthine method was previously used to assess the AQMs 1 antimalarial activities. To be able to compare the AQMs 1 and AFMs 2, as these two methods were different, relative antimalarial activity indexes were calculated and compared respectively to MQ (for 3D7) and to CQ (for W2).
The AFMs were active on the nanomolar range with a slightly higher efficacy against 3D7 strains for (S)-enantiomers ( Table 2 ). The (S)-AFMs 2a and 2b had activities similar to their analogues (S)-AQMs 1b and 1c. Interestingly, the (S)-AFMs displayed an activity increased by 1.6 to 3.9-fold as compared to their (R)-counterparts. So, a fluorene is a promising core for antimalarial activity. It is beneficial for the corresponding (R)-enantiomers. The (S)-compounds were generally more actives that LM, MQ and CQ on 3D7 and W2. The AFMs were not cytotoxic on HepG2 cells (a human liver cancer cell line) with selectivity indexes superiors to 100 (Table 3) .
ENANTIOSELECTIVE AFMs SYNTHESIS

RESULTS
Product IC 50 (nM)
Pf3D7
Pf W2 MQ 61.0 ± 7.1 21.1 ± 5.0 LM 28.7 ± 3.5 39.9 ± 2.8 CQ 17.0 ± 4.6 404.5 ± 55.2 (R)-2a (n = 3) 33.0 ± 6.2 30.7 ± 3.3 (S)-2a (n = 3) 8.5 ± 1.8 23.3 ± 4.5 (R)-2b (n = 4) 22.3 ± 2.5 25.5 ± 3.9 (S)-2b (n = 4) 14.0 ± 2.7 19.3 ± 4.8
To obtain the enantiopure AFMs, the first step was a chloration from commercial fluorene 3 in position two and seven (Step A). Then a Friedel-Craft acylation and reduction give the compound 6. The vinyl 7 was prepared via 6 dehydratation (Step C). Then, an asymmetric Sharpless dihydroxylation was performed to give the diols (S)-8 and (R)-8 in 95% yields (ee > 97%) ( Step D). The epoxides 9 were obtained after a one-pot synthesis (in three reaction steps) in good yields and enantiomeric purities superior to 95% (Step E). A nucleophilic addition, by microwave assistance, in the presence of a primary amine gave the enantiopure AFMs 2 (Step F). Currently, we obtained 10 AFMs 2 with good yields and very good enantiomeric excess (ee > 98%). 
CONCLUSION
In this work, an asymmetric route to access the AFMs was developed. We obtained 10 AFMs, in 7 steps, with 17% to 56% of global yields and enantiomeric excess superior to 90%. Preliminary antimalarial results for AFM 2a and AFM 2b showed high activities on the nanomolar range that confirm the interest of the fluorene core in the research of new antimalarial drugs. The importance of the stereochemistry was showed with high activity for (S)-enantiomers. The AFMs presented a low cytotoxicity in vitro on HepG2. In the continuation of our work, we will complete their toxicity and in vivo evaluations. 
Product
IC 50 (µM) Selectivity indexes 2 HepG2 MQ 11.9 ± 6.9 195 (R)-2a 4.82 ± 1.0 142 (R)-2b 6.7 ± 4.5 3164 (S)-2b 5.0 ± 1.6 520 
